SAIPARENT · Sai Parenterals Ltd · Biotechnology & Drugs
SAIPARENT · Sai Parenterals Ltd · Biotechnology & Drugs
As of 05 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹179 Cr
Revenue YoY
PAT YoY
+459.9%
Operating margin
Revenue, last 5 quarters
Source: Yahoo Finance, as of 30 Jun 2026
P/E (TTM)
P/B
7.1
P/S (TTM)
4.4
Sector P/E
36.3
Dividend yield
0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SAIPARENT (this stock) | 119.9 | 7.1 | +4.0% | Not available from data source | 0.96 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
0.98% (-2.83pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| SAIPARENT | 2026-07-02 | 105392 | 1 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: During the earnings conference call held on August 12, 2026, management reported that Sai Parenterals Limited achieved consolidated total revenue of Rs. 182 crores for Q1 FY '27, a decrease from Rs. 201 crores in Q4 FY '26. Gross profit was Rs. 76 crores with a gross margin of 41.8%, and EBITDA was Rs. 27 crores at a margin of 14.9%. Management noted that the first quarter represented approximately 24% of their full-year revenue goal of Rs. 750 crores. They discussed strategic developments, including a proposed variation in IPO fund usage to acquire stakes in two pharmaceutical assets, which management stated would enhance capacity and capabilities. The company also provided updates on their Australian facility, which is on schedule for completion in January 2027. Management reiterated their revenue guidance of Rs. 750 crores for FY '27 with an EBITDA margin of around 17%.
Management provided a detailed overview of financial performance and strategic initiatives without strong emphasis on growth or challenges.
Sourced from an exchange-filed transcript, dated 18 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: On August 12, 2026, Sai Parenterals Limited submitted an investor presentation detailing its financial results for the quarter ended June 30, 2026. The presentation highlighted the company's end-to-end business model, which includes R&D, manufacturing, regulatory, and sales functions. Management reported a total of 302 products across nine therapeutic areas and over 599 registrations in regulated and semi-regulated markets. The company emphasized its long-term contracted revenue, with over 50% of consolidated revenue secured through agreements. Key acquisitions were discussed, including a 60% stake in Saicriti Pharma for a new injectable facility and Prathyak Laboratories for R&D capabilities. The presentation also outlined a Rs. 571 crore capex program aimed at expanding manufacturing capacity and enhancing R&D. Management reiterated its revenue guidance of Rs. 750 crore for FY27, with an EBITDA margin of around 17%.
Management emphasized growth and strategic initiatives in the presentation.
Sourced from an exchange-filed presentation, dated 12 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Sai Parenterals Limited, dated May 26, 2026, disclosed the financial results for the quarter and year ended March 31, 2026. Management reported consolidated revenue of ₹198 crore for Q4FY26 and ₹381 crore for FY26, marking a significant growth platform. Standalone revenue, EBITDA, and PAT for FY26 increased by 31%, 23%, and 64%, respectively, driven by strong growth in the Contract Development and Manufacturing Organization (CDMO) segment, which surged over 250% year-on-year. The company expanded its portfolio by 93 dossiers in FY26 and secured long-term CDMO contracts, enhancing revenue visibility. The presentation highlighted ongoing facility upgrades and the establishment of a new R&D center to support future growth. Management emphasized the strategic acquisition of Noumed Pharmaceuticals, which strengthens their global CDMO capabilities and market access in Australia and New Zealand.
Management highlighted strong financial growth and strategic expansions.
Sourced from an exchange-filed presentation, dated 26 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedSai Parenterals Limited, a diversified multinational pharmaceutical company, highlights its transition to a listed entity, enhancing visibility and opportunities. The company focuses on expanding access to regulated markets, advancing its injectables portfolio, deepening R&D, scaling CDMO operations, and integrating international operations. Strategic priorities include completing European GMP upgrades, commissioning an Adelaide facility, and leveraging Australian approvals for faster market entry. The report emphasizes governance, compliance, and stakeholder engagement, with a commitment to quality and disciplined growth.
- Expansion into regulated markets through GMP upgrades and international operations
- Strategic focus on CDMO scaling and injectables portfolio advancement
- Commitment to quality, execution, and responsible capital use for sustainable growth
- Enhanced corporate governance with specialized board committees and policies
Key takeaway: Sai Parenterals is strategically positioning itself for growth through regulated market expansion, CDMO scaling, and robust governance, while navigating industry challenges like competition and regulatory compliance.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has contingent liabilities, including claims against it not acknowledged, as of March 31, 2026.
The company has contingent liabilities related to its term loan from Kotak Bank and Tata Capital, secured by paripassu charges on fixed and current assets, shares of Noumed Pharmaceuticals Pty Ltd, and promoters' personal guarantees.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company is considering a material related party transaction involving the grant of a loan to SAI Singapore Pte. Ltd. for downstream funding to Noumed Pharmaceuticals Pty. Limited, Australia.
The company is considering a material related party transaction involving the grant of a loan to SAI Singapore PTE. Ltd. for downstream funding to Noumed Pharmaceuticals Pty. Limited, Australia.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Mr. Kunal Kakumanu, an Executive Director, resigned effective 11.08.2026.